Apparently MTG got an upgrade, which set this all up. A double in a few days, trading on hope taken to the extreme.

You were very right on this one, $F. Volatility central here: think the big boys are having huge fun here.

Amazing it's just abovethe point where it started bouncing, and even lower than Friday's open; Ouch.

Could be we get a hope bounce, or just big boys playing.

GMXR -24% PM

Now that was a momo play! Hope no-one here ended up stuck.

Patiently waiting, huh. I see earnings on the 18th, could be the push it needs?

Nice info kei, thanks.

Bios are running like nuts, the big boys too (CELG, BMRN, ILMN etc.). Lots of strength in the sector, especially for those wth catalysts.

If DCTH manages to break out, could be a very nice pre-ER run. Just a bit wary because it's shown it likes to disappoint and kill runs just like that.

Ever, that's the right word indeed.

As for the one stock, I should know it but I see so many stocks nowadays on a daily basis, tough to keep 'em in order.

If it isn't metals related or AAPL, then the only way is up.

Love how they ignored China data, for instance. It's really an effort for me to let go of reticence and just buy cos any dip will be bought.

Fundawhat?

Buy, buy, buy, or be run over by the machines :) Hope indeed.

Volume really strong, real interest + momo plays nowadays are freaking nuts.

A few on watch

Shame about the post ER selling, but it was becoming a bit frenzied. Definitely has a thing for the 50MA :)

Could be it's in consolidation mode till the 50MA pushes again.

What a move since December. Some profitable 20MA bounces.

Think SA been more focused on this one too lately?

Nice gain. Bios seem very strong lately.

Shame this one's not seen continuation, still stuck in the same range.

One of the most impressive comebacks in a while. That conference call must've been golden.

That break over 3.35 really cements the range break. Thinking 4.40s doable, possibly after a resting period first.

NEWL: guess a China play will always be decided on the flip of a coin... Never came close to repeating the January moves.

NEWL announces delivery contract to generate $148M in revenue

Up in PM, worth the watch.

Most of the fun in PM?

Perhaps needs a bit of time; we've had plenty of those.

Nice % gains for those who dared buy around 7:30.

Good green volume after 8AM, as if the floodgates opened :) Damn, this stock used to be in 20s as well as $3s. Quite the range.

BTW: "$AFFY Downgraded to Neutral at Piper Jaffray, $37 PT removed" LOL.

DRTX announces preliminary Phase 3 results for Dalbavacin

Durata Therapeutics announced preliminary, top-line results for its "Dalbavancin for Infections of the Skin Compared to Vancomycin at an Early Response", or DISCOVER 2, Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible gram-positive bacteria, including methicillin resistant Staphylococcus aureus, or MRSA. DISCOVER 2 results follow the recent release of data from DISCOVER 1, which also met its primary and secondary endpoints. Preliminary top-line data show that dalbavancin achieved its primary endpoint of non-inferiority at 48-72 hours after initiation of therapy, as determined by the cessation of spread of the lesion, as well as the resolution of fever. Researchers were comparing two intravenous doses of dalbavancin given one week apart with twice-daily vancomycin doses for 14 days. Patients randomized to the vancomycin regimen had an option to switch to oral linezolid after three days of vancomycin treatment. In addition, the trial assessed as a secondary outcome measure the non-inferiority of clinical response at the end of treatment in clinically evaluable patients. Dalbavancin also achieved this secondary endpoint.

Same to you :)

DVAX -37%

CRL, next bio to crash :)

Also watch SRPT, may be a mover today too.

AFFY: -75%

Still early, but ouch nonetheless.

APPY Upgraded to Buy at Canaccord, PT Raised to $7

Worth watching, upgrades on these baby bios sometimes make them go wild.

Yeah, know that one, indeed a nice list.

And never forget these are pinkies, the big % moves are usually in the wrong direction :)

CBMX SA article author is out.

At least he's honest.

Wow, vicious selling. Guess when it becomes predictable, they mix it up.

Reminds me of CALI, I think?

Not quite there yet, but what a move. Congrats guys!!

I'll give you one thing, pinkies confirm time and again that what takes ages to build may be destroyed in a day.

Doesn't seem like a P&D but a real company hitting bad news?

Does look like it could see .40 again.

Pluristem receives FDA orphan drug designation for treatment of aplastic anemia

Me too. Saw the news in passing, but didn't really read that carefully :)

Nice upgrades too:

No bounce yet, though did hold the 50MA (FWIW in pinky land :))

Still got good hopes for this one considering the re-pumping lately.

CRTX receives take-private proposal of $6.40-$6.70 per share

Cornerstone Therapeutics announced that its board has received a letter from Chiesi Farmaceutici SpA. In that letter Chiesi, which owns approximately 60% of the outstanding shares of the company's common stock, made a proposal, subject to certain conditions, to acquire the shares of the company's common stock that it does not already own for a cash purchase price of between $6.40-$6.70 per share. The company cautions its stockholders and others considering trading in its common stock that no decisions have been made by the board with respect to Chiesi's proposal. There can be no assurance that any agreement will result from the proposal submitted by Chiesi or that any transaction based on Chiesi's proposal will be consummated.

Yeah, seen that one indeed. Seems like the initial earnings reaction was negative, but then came the Buy ratings and crazy up since.

13.57 is a resistance point, 200wMA @ 14.37. Always tricky when it's at this point, up almost 70% in such a short time.

INFI: +16%

What one upgrade does in this market:

Kudos to $F for his tenacity with IGC.

People may see -7% on their scans, but the intra-day shows an uglier picture. Yuck.

GNIN bounce play?

Another nutty chart. Risky, as always.

BBY moving pre-market

More upgrades, PT of $20 mentioned by analysts, this move past the 200MA may well be the next leg up. $18 first target.

I usually assume they either missed the run and are envious or are now out after banking.

0.01% chance it's genuine concern ;)

OSIR designated as Orphan Drug title holder by EMA

Looking like a gap up in PM, right now anyway.

Osiris Therapeutics announced that the European Medicines Agency, or EMA, has designated Osiris as the Orphan Drug title holder for Prochymal. The EU Commission adopted the decision to transfer the designation of Prochymal as an orphan medicinal product under Regulation, or EC, No 141/2000 of the European Parliament and of the Council. The Decision will appear in the EU Community Register of Orphan Medicinal Products.